Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and discusses late breaker presentations around atopic dermatitis and prurigo nodularis.
EADV 2023 Day 1 Afternoon: Late Breaking HS and Alopecia Developments
Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and discusses the late breaker presentations about hidradenitis suppurativa and alopecia areata.
EADV 2023 Day 1 Morning: The Pathogenesis of Psoriasis
Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and gives insights into the International Psoriasis Council presentations regarding the pathogenesis of psoriasis.
HS disease burden and costs continue to increase after diagnosis
According to a new study, hidradenitis suppurativa (HS) comorbidity burden and healthcare resource utilizations costs continue to increase after diagnosis.
Suppressing key metabolic enzyme may stop melanoma growth, new study shows
A new study has discovered that by inhibiting the key metabolic enzyme Glutaryl-CoA Dehydrogenase (GCDH), melanoma cells can be selectively killed to halt tumour growth.
Patients with HS at higher risk of myocardial infarction, new study shows
A new study suggests that patients with hidradenitis suppurativa (HS) are at a significantly higher risk of myocardial infarction (MI), but not cerebrovascular accident or peripheral vascular disease as previous studies have shown.
Thirdhand smoke exposure can cause skin damage
According to a new study concentrations of nicotine that settle on surfaces, also called thirdhand smoke (THS), as well as electronic cigarette spills can damage the skin.
University of Toronto establishes Chair in Ethnodermatology position
The University of Toronto has just established the AbbVie Chair in Ethnodermatology, one of the first positions of its kind, to support diversity in dermatology training, research and care, according to a press release.
Researchers review HS biomarkers and criteria for validation in clinical trials
Researchers have reviewed the literature on biomarkers for hidradenitis suppurativa (HS) to evaluate the validity of these biomarkers and to identify the reasons for their lack of use in clinical trials.
Dupilumab reduces hospitalizations in patients with AD, according to new study
According to a new study, adult patients with moderate-to-severe atopic dermatitis (AD) being treated with dupilumab had lower rates of hospitalization and shorter stays when compared to those not on dupilumab.
HealthMinute.TV 